170 related articles for article (PubMed ID: 15288829)
21. Improvement of radiation treatment planning in squamous-cell head and neck cancer by immuno-SPECT.
Adamietz IA; Baum RP; Schemman F; Niesen A; Knecht R; Saran F; Tieku S; Boniface GR; Hör G; Böttcher HD
J Nucl Med; 1996 Dec; 37(12):1942-6. PubMed ID: 8970510
[TBL] [Abstract][Full Text] [Related]
22. Radioimmunolocalization of primary and metastatic breast cancer.
Baum RP; Brümmendorf TH
Q J Nucl Med; 1998 Mar; 42(1):33-42. PubMed ID: 9646643
[TBL] [Abstract][Full Text] [Related]
23. New insights into the pretargeting approach to image and treat tumours.
Patra M; Zarschler K; Pietzsch HJ; Stephan H; Gasser G
Chem Soc Rev; 2016 Nov; 45(23):6415-6431. PubMed ID: 27722526
[TBL] [Abstract][Full Text] [Related]
24. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies.
Verel I; Visser GW; Boellaard R; Stigter-van Walsum M; Snow GB; van Dongen GA
J Nucl Med; 2003 Aug; 44(8):1271-81. PubMed ID: 12902418
[TBL] [Abstract][Full Text] [Related]
25. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients.
Börjesson PK; Jauw YW; Boellaard R; de Bree R; Comans EF; Roos JC; Castelijns JA; Vosjan MJ; Kummer JA; Leemans CR; Lammertsma AA; van Dongen GA
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2133-40. PubMed ID: 16609026
[TBL] [Abstract][Full Text] [Related]
26. Immuno-PET: a navigator in monoclonal antibody development and applications.
van Dongen GA; Visser GW; Lub-de Hooge MN; de Vries EG; Perk LR
Oncologist; 2007 Dec; 12(12):1379-89. PubMed ID: 18165614
[TBL] [Abstract][Full Text] [Related]
27. Lymph node staging in extracranial head and neck cancer with FDG PET--appropriate uptake period and size-dependence of the results.
Brink I; Klenzner T; Krause T; Mix M; Ross UH; Moser E; Nitzsche EU
Nuklearmedizin; 2002 Apr; 41(2):108-13. PubMed ID: 11989297
[TBL] [Abstract][Full Text] [Related]
28. Perspectives of monoclonal antibodies for detection and treatment of head and neck tumours.
Quak J; Gerretsen M; De Bree R; Brakenhof R; Van Dongen G; Snow G
Anticancer Res; 1993; 13(6B):2533-9. PubMed ID: 8135493
[TBL] [Abstract][Full Text] [Related]
29. [Value of SPECT-immunoscintigraphy in radiation treatment planning for patients with squamous cell carcinomas in the head and neck area].
Adamietz IA; Schemmann F; Baum RP; Knecht R; Saran F; Mose S; Thilmann C; Hör G; Böttcher HD
Strahlenther Onkol; 1995 May; 171(5):278-83. PubMed ID: 7770783
[TBL] [Abstract][Full Text] [Related]
30. A model for others: a strategy for improving diagnosis and therapy of human malignancies using monoclonal antibodies targeting TAG-72 oncofetal antigen.
Larson SM
Cancer Invest; 1993; 11(2):235-8. PubMed ID: 8462025
[No Abstract] [Full Text] [Related]
31. Immunoscintigraphy and radioimmunotherapy in Cuba: experiences with labeled monoclonal antibodies for cancer diagnosis and treatment (1993-2013).
Peña Y; Perera A; Batista JF
MEDICC Rev; 2014; 16(3-4):55-60. PubMed ID: 25208121
[TBL] [Abstract][Full Text] [Related]
32. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
Tijink BM; Neri D; Leemans CR; Budde M; Dinkelborg LM; Stigter-van Walsum M; Zardi L; van Dongen GA
J Nucl Med; 2006 Jul; 47(7):1127-35. PubMed ID: 16818947
[TBL] [Abstract][Full Text] [Related]
33. The current status of positron-emission tomography scanning in the evaluation and follow-up of patients with head and neck cancer.
Kutler DI; Wong RJ; Schoder H; Kraus DH
Curr Opin Otolaryngol Head Neck Surg; 2006 Apr; 14(2):73-81. PubMed ID: 16552262
[TBL] [Abstract][Full Text] [Related]
34. Safety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients.
Stroomer JW; Roos JC; Sproll M; Quak JJ; Heider KH; Wilhelm BJ; Castelijns JA; Meyer R; Kwakkelstein MO; Snow GB; Adolf GR; van Dongen GA
Clin Cancer Res; 2000 Aug; 6(8):3046-55. PubMed ID: 10955783
[TBL] [Abstract][Full Text] [Related]
35. Head and neck cancer localization with indium labelled carcinoembryonic antigen: a pilot project.
Timon CI; McShane D; Hamilton D; Walsh MA
J Otolaryngol; 1991 Aug; 20(4):283-7. PubMed ID: 1920585
[TBL] [Abstract][Full Text] [Related]
36. [Immunoscintigraphic detection of metastasis in malignant melanoma in the head and neck area].
Rosanowski F; Briele B; Walther EK
Laryngorhinootologie; 1994 Feb; 73(2):94-7. PubMed ID: 8161416
[TBL] [Abstract][Full Text] [Related]
37. A comparative diagnostic study of head and neck nodal metastases using positron emission tomography.
McGuirt WF; Williams DW; Keyes JW; Greven KM; Watson NE; Geisinger KR; Cappellari JO
Laryngoscope; 1995 Apr; 105(4 Pt 1):373-5. PubMed ID: 7715380
[TBL] [Abstract][Full Text] [Related]
38. Improved tumor targeting by combined use of two antitenascin antibodies.
Petronzelli F; Pelliccia A; Anastasi AM; D'Alessio V; Albertoni C; Rosi A; Leoni B; De Angelis C; Paganelli G; Palombo G; Dani M; Carminati P; De Santis R
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7137s-7145s. PubMed ID: 16203813
[TBL] [Abstract][Full Text] [Related]
39. Radioimmunoscintigraphy in patients with ovarian cancer.
Kalofonos HP; Karamouzis MV; Epenetos AA
Acta Oncol; 2001; 40(5):549-57. PubMed ID: 11669325
[TBL] [Abstract][Full Text] [Related]
40. Potential of immuno-positron emission tomography for tumor imaging and immunotherapy planning.
Zalutsky MR
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1958-60. PubMed ID: 16609003
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
